JP2003535885A5 - - Google Patents

Download PDF

Info

Publication number
JP2003535885A5
JP2003535885A5 JP2002503259A JP2002503259A JP2003535885A5 JP 2003535885 A5 JP2003535885 A5 JP 2003535885A5 JP 2002503259 A JP2002503259 A JP 2002503259A JP 2002503259 A JP2002503259 A JP 2002503259A JP 2003535885 A5 JP2003535885 A5 JP 2003535885A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
gabapentin
composition according
weight
corresponding lactam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002503259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/019427 external-priority patent/WO2001097782A1/en
Publication of JP2003535885A publication Critical patent/JP2003535885A/ja
Publication of JP2003535885A5 publication Critical patent/JP2003535885A5/ja
Pending legal-status Critical Current

Links

JP2002503259A 2000-06-16 2001-06-15 制御された範囲内にｐＨを持つ安定なギャバペンチン Pending JP2003535885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21196600P 2000-06-16 2000-06-16
US60/211,966 2000-06-16
PCT/US2001/019427 WO2001097782A1 (en) 2000-06-16 2001-06-15 Stable gabapentin having ph within a controlled range

Publications (2)

Publication Number Publication Date
JP2003535885A JP2003535885A (ja) 2003-12-02
JP2003535885A5 true JP2003535885A5 (enExample) 2006-01-19

Family

ID=22788986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002503259A Pending JP2003535885A (ja) 2000-06-16 2001-06-15 制御された範囲内にｐＨを持つ安定なギャバペンチン

Country Status (18)

Country Link
US (4) US20020045662A1 (enExample)
EP (1) EP1294364A4 (enExample)
JP (1) JP2003535885A (enExample)
KR (2) KR20060123782A (enExample)
CN (1) CN1447684A (enExample)
AU (2) AU6699201A (enExample)
CA (1) CA2411787C (enExample)
CZ (1) CZ200339A3 (enExample)
HR (1) HRP20030002A2 (enExample)
HU (1) HUP0301919A3 (enExample)
IL (1) IL153441A0 (enExample)
IS (1) IS6654A (enExample)
NZ (1) NZ523546A (enExample)
PL (1) PL363155A1 (enExample)
SK (1) SK302003A3 (enExample)
WO (1) WO2001097782A1 (enExample)
YU (1) YU95302A (enExample)
ZA (1) ZA200210144B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
EP1494996A1 (en) * 2002-04-16 2005-01-12 Taro Pharmaceutical Industries Limited Process for preparing gabapentin
KR20050084445A (ko) * 2002-12-20 2005-08-26 다이노젠 파마세우티컬스, 인코포레이티드 α₂δ 서브유닛 칼슘 채널 모듈레이터를 이용한 무통증방광 질환의 치료방법
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
WO2005117526A2 (en) * 2004-06-03 2005-12-15 Matrix Laboratories Ltd An improved process for the purification of gabapentin
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EP1729735B1 (en) * 2004-11-10 2007-06-27 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20080103334A1 (en) * 2006-10-26 2008-05-01 Ipca Laboratories Ltd Process For Synthesis Of Gabapentin
WO2008106217A1 (en) * 2007-02-28 2008-09-04 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin by liquid-liquid extraction

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2611690A1 (de) * 1976-03-19 1977-09-22 Goedecke Ag Cyclische sulfonyloxyimide
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) * 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US5319135A (en) * 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
MY106864A (en) * 1989-08-25 1995-08-30 Warner Lambert Co Improved process for cyclic amino acid anticonvulsant compounds.
DE3928182A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
DE3928184A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von cyclischen aminosaeurederivaten sowie zwischenprodukte
FI905584L (fi) * 1989-11-16 1991-05-17 Lonza Ag Foerfarande foer framstaellning av 1-(aminometyl)cyklohexanaettikssyra.
US5149870A (en) * 1989-11-16 1992-09-22 Lonza Ltd. Process for the production of 1-(aminomethyl)cyclohexane acetic acid
US5136091A (en) * 1989-11-16 1992-08-04 Lonza Ltd. Process for the production of 1-(aminomethyl) cyclohexane acetic acid
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
US6294690B1 (en) * 1997-10-07 2001-09-25 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
HU228772B1 (en) * 1998-05-15 2013-05-28 Warner Lambert Co Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
DK1077692T3 (da) * 1998-05-15 2004-12-06 Warner Lambert Co Aminosyrestabiliserede gabapentin- og pregabalinpræparater og fremgangsmåder til fremstilling deraf
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
HU225502B1 (en) * 1998-12-29 2007-01-29 Richter Gedeon Vegyeszet Process for producing 1-(amino-metyl)-cyclohexene-acetic-acid and intermediates
ES2164527B1 (es) * 1999-04-26 2003-04-01 Medichen S A Procedimiento de obtencion de gabapentina de calidad farmaceutica.
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
PT1289364E (pt) * 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto

Similar Documents

Publication Publication Date Title
JP2003535885A5 (enExample)
JP2023062189A5 (enExample)
JP2005520796A5 (enExample)
JP2005508331A5 (enExample)
JP2005538104A5 (enExample)
JP2007504212A5 (enExample)
JP2011500583A5 (enExample)
JP3874793B2 (ja) イブプロフェンおよびコデイン含有の改良された医薬処方
JP2009545560A5 (enExample)
FI2498756T4 (fi) Neratinibimaleaatin tablettiformulaatiot
JP2006522006A5 (enExample)
JP2009526021A5 (enExample)
JP2010511631A5 (enExample)
JP2003535895A5 (enExample)
JP2016530238A5 (enExample)
JP2004532828A5 (enExample)
ES2197087T3 (es) Tabletas tragables con alto contenido de n-acetilcisteina.
ES2248850T3 (es) Formulaciones farmaceuticas que contienen sales de potasiom sodio y tris de oxaprozina.
JPWO2012141160A1 (ja) ピタバスタチン含有製剤及びその製造方法
JP2004505922A5 (enExample)
JP2008500287A5 (enExample)
CA2566331A1 (en) Oral delivery system
JP2004522780A5 (enExample)
JP2009519985A5 (enExample)
CN110446701A (zh) 一种2-氨基嘧啶类化合物的药用组合物及其制备方法